Main clues in the pathologic diagnosis of melanoma: is molecular genetics helping?
Article first published online: 9 OCT 2012
© 2012 Wiley Periodicals, Inc.
Special Issue: Understanding and Treating Malignant Melanoma
Volume 25, Issue 5, pages 423–431, September/October 2012
How to Cite
Ferrara, G., Senetta, R., Paglierani, M. and Massi, D. (2012), Main clues in the pathologic diagnosis of melanoma: is molecular genetics helping?. Dermatologic Therapy, 25: 423–431. doi: 10.1111/j.1529-8019.2012.01485.x
- Issue published online: 9 OCT 2012
- Article first published online: 9 OCT 2012
- comparative genome hybridization;
- fluorescence in situ hybridization;
- melanocytic nevi;
- molecular classification
Although conventional histopathologic examination is still the undisputable mainstay for the diagnosis of melanocytic skin neoplasms, application of molecular testing has experienced tremendous growth and will continue to expand in the future as the need for more specific diagnoses and new targeted therapies evolve. Ancillary molecular methods, including comparative genomic hybridization and fluorescence in situ hybridization, have the potential to provide important new information to challenging cases, and will help improve diagnostic accuracy, particularly in cases in which morphology is not conclusive. Pathologists are increasingly involved in the prospective genotyping of melanoma, which leads to patient stratification in light of the novel personalized therapeutic approaches in the advanced setting.